Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 85

1.

Tumor image signatures and habitats: a processing pipeline of multimodality metabolic and physiological images.

You D, Kim MM, Aryal MP, Parmar H, Piert M, Lawrence TS, Cao Y.

J Med Imaging (Bellingham). 2018 Jan;5(1):011009. doi: 10.1117/1.JMI.5.1.011009. Epub 2017 Nov 15.

PMID:
29181433
2.

Associations between apparent diffusion coefficient (ADC) and KI 67 in different tumors: a meta-analysis. Part 1: ADCmean.

Surov A, Meyer HJ, Wienke A.

Oncotarget. 2017 Aug 24;8(43):75434-75444. doi: 10.18632/oncotarget.20406. eCollection 2017 Sep 26.

3.
4.

Neurologic Applications of PET/MR Imaging.

Miller-Thomas MM, Benzinger TL.

Magn Reson Imaging Clin N Am. 2017 May;25(2):297-313. doi: 10.1016/j.mric.2016.12.003. Epub 2017 Jan 26. Review.

PMID:
28390530
5.

Differentiation of pseudoprogression and real progression in glioblastoma using ADC parametric response maps.

Reimer C, Deike K, Graf M, Reimer P, Wiestler B, Floca RO, Kickingereder P, Schlemmer HP, Wick W, Bendszus M, Radbruch A.

PLoS One. 2017 Apr 6;12(4):e0174620. doi: 10.1371/journal.pone.0174620. eCollection 2017.

6.

Semiautomated Workflow for Clinically Streamlined Glioma Parametric Response Mapping.

Keith L, Ross BD, Galbán CJ, Luker GD, Galbán S, Zhao B, Guo X, Chenevert TL, Hoff BA.

Tomography. 2016 Dec;2(4):267-275. doi: 10.18383/j.tom.2016.00181.

7.

Feasibility evaluation of diffusion-weighted imaging using an integrated MRI-radiotherapy system for response assessment to neoadjuvant therapy in rectal cancer.

Shaverdian N, Yang Y, Hu P, Hart S, Sheng K, Lamb J, Cao M, Agazaryan N, Thomas D, Steinberg M, Low DA, Lee P.

Br J Radiol. 2017 Mar;90(1071):20160739. doi: 10.1259/bjr.20160739. Epub 2017 Jan 12.

PMID:
28079398
8.

Progressing Bevacizumab-Induced Diffusion Restriction Is Associated with Coagulative Necrosis Surrounded by Viable Tumor and Decreased Overall Survival in Patients with Recurrent Glioblastoma.

Nguyen HS, Milbach N, Hurrell SL, Cochran E, Connelly J, Bovi JA, Schultz CJ, Mueller WM, Rand SD, Schmainda KM, LaViolette PS.

AJNR Am J Neuroradiol. 2016 Dec;37(12):2201-2208. Epub 2016 Aug 4.

9.

Markers of Response to Antiangiogenic Therapies in Colorectal Cancer: Where Are We Now and What Should Be Next?

Cidon EU, Alonso P, Masters B.

Clin Med Insights Oncol. 2016 Apr 27;10(Suppl 1):41-55. doi: 10.4137/CMO.S34542. eCollection 2016. Review.

10.

Imaging of oligodendroglioma.

Smits M.

Br J Radiol. 2016;89(1060):20150857. doi: 10.1259/bjr.20150857. Epub 2016 Feb 5. Review.

11.

Diffusion MRI in early cancer therapeutic response assessment.

Galbán CJ, Hoff BA, Chenevert TL, Ross BD.

NMR Biomed. 2017 Mar;30(3). doi: 10.1002/nbm.3458. Epub 2016 Jan 15. Review.

PMID:
26773848
12.

Association of Diffusion and Anatomic Imaging Parameters with Survival for Patients with Newly Diagnosed Glioblastoma Participating in Two Different Clinical Trials.

Wen Q, Jalilian L, Lupo JM, Li Y, Roy R, Molinaro AM, Chang SM, Prados M, Butowski N, Clarke J, Nelson SJ.

Transl Oncol. 2015 Dec;8(6):446-55. doi: 10.1016/j.tranon.2015.10.001.

13.

Development of a Multiparametric Voxel-Based Magnetic Resonance Imaging Biomarker for Early Cancer Therapeutic Response Assessment.

Galbán CJ, Lemasson B, Hoff BA, Johnson TD, Sundgren PC, Tsien C, Chenevert TL, Ross BD.

Tomography. 2015 Sep;1(1):44-52.

14.

Physiologic MRI for assessment of response to therapy and prognosis in glioblastoma.

Shiroishi MS, Boxerman JL, Pope WB.

Neuro Oncol. 2016 Apr;18(4):467-78. doi: 10.1093/neuonc/nov179. Epub 2015 Sep 12. Review.

15.

Multimodality Brain Tumor Imaging: MR Imaging, PET, and PET/MR Imaging.

Fink JR, Muzi M, Peck M, Krohn KA.

J Nucl Med. 2015 Oct;56(10):1554-61. doi: 10.2967/jnumed.113.131516. Epub 2015 Aug 20. Review.

16.

Automated Feature Extraction in Brain Tumor by Magnetic Resonance Imaging Using Gaussian Mixture Models.

Chaddad A.

Int J Biomed Imaging. 2015;2015:868031. doi: 10.1155/2015/868031. Epub 2015 Jun 2. Erratum in: Int J Biomed Imaging. 2017;2017:3247974.

17.

Integrated multimodal imaging of dynamic bone-tumor alterations associated with metastatic prostate cancer.

Brisset JC, Hoff BA, Chenevert TL, Jacobson JA, Boes JL, Galbán S, Rehemtulla A, Johnson TD, Pienta KJ, Galbán CJ, Meyer CR, Schakel T, Nicolay K, Alva AS, Hussain M, Ross BD.

PLoS One. 2015 Apr 10;10(4):e0123877. doi: 10.1371/journal.pone.0123877. eCollection 2015.

18.

Multi-site clinical evaluation of DW-MRI as a treatment response metric for breast cancer patients undergoing neoadjuvant chemotherapy.

Galbán CJ, Ma B, Malyarenko D, Pickles MD, Heist K, Henry NL, Schott AF, Neal CH, Hylton NM, Rehemtulla A, Johnson TD, Meyer CR, Chenevert TL, Turnbull LW, Ross BD.

PLoS One. 2015 Mar 27;10(3):e0122151. doi: 10.1371/journal.pone.0122151. eCollection 2015.

19.

Lessons from anti-vascular endothelial growth factor and anti-vascular endothelial growth factor receptor trials in patients with glioblastoma.

Lu-Emerson C, Duda DG, Emblem KE, Taylor JW, Gerstner ER, Loeffler JS, Batchelor TT, Jain RK.

J Clin Oncol. 2015 Apr 1;33(10):1197-213. doi: 10.1200/JCO.2014.55.9575. Epub 2015 Feb 23.

20.

sfDM: Open-Source Software for Temporal Analysis and Visualization of Brain Tumor Diffusion MR Using Serial Functional Diffusion Mapping.

Ceschin R, Panigrahy A, Gopalakrishnan V.

Cancer Inform. 2015 Feb 1;14(Suppl 2):1-9. doi: 10.4137/CIN.S17293. eCollection 2015.

Supplemental Content

Support Center